Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase I data presented for ambrisentan in sickle cell disease

Jan. 2, 2020

Autolus presents phase I data from Amelia study of AUTO-3 in pediatric patients

Jan. 2, 2020

Metformin, explained

Jan. 2, 2020

Anthos Therapeutics studies MAA-868 in phase II for atrial fibrillation

Dec. 31, 2019

CTX-712: a novel promising CLK inhibitor for myeloid tumors

Dec. 31, 2019

BioXcel begins phase III program with BXCL-501 for agitation in schizophrenia and bipolar disorder

Dec. 31, 2019

FDA approves OncoImmune's IND for anti-CTLA-4 antibody ONC-392

Dec. 31, 2019

Hookipa begins dosing in phase I/II trial of HB-201 for HPV16-positive cancers

Dec. 31, 2019

New phase Ib study evaluates mavorixafor with ibrutinib for Waldenstrom's macroglobulinemia

Dec. 31, 2019

Principia advances PRN-1008 for pemphigus with accelerated enrollment in phase III study

Dec. 31, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...